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Alzheimer’s disease (AD) is associated with cognitive dysfunction. Evidence indicates
that gut microbiota is altered in the AD and, hence, modifying the gut flora may
affect the disease. In the previous clinical research we evaluated the effect of a
probiotic combination on the cognitive abilities of AD patients. Since, in addition to
pathological disorders, the AD is associated with changes in oxidant/antioxidant and
inflammatory/anti-inflammatory biomarkers, the present work was designed to evaluate
responsiveness of the inflammatory and oxidative biomarkers to the probiotic treatment.
The control (CON) and probiotic (PRO) AD patients were treated for 12 weeks by
the placebo and probiotic supplementation, respectively. The patients were cognitively
assessed by Test Your Memory (TYM = 50 scores). Also serum concentrations of
nitric oxide (NO), glutathione (GSH), total antioxidant capacity (TAC), malondialdehyde
(MDA), 8-hydroxy-2
′
-deoxyguanosine (8-OHdG) and cytokines (TNF-a, IL-6, and IL-10)
were measured. The cognitive test and the serum biomarkers were assessed pre- and
post-treatment. According to TYM test 83.5% of the patients showed severe AD. The
CON (12.86% ± 8.33) and PRO (−9.35% ± 16.83) groups not differently scored the
cognitive test. Not pronounced change percent was found in the serum level of TNF-
α (1.67% ± 1.33 vs. −0.15% ± 0.27), IL-6 (0.35% ± 0.17 vs. 2.18% ± 0.15), IL-10
(0.05% ± 0.10 vs. −0.70% ± 0.73), TAC (0.07% ± 0.07 and −0.06% ± 0.03), GSH
(0.08% ± 0.05 and 0.04% ± 0.03) NO (0.11% ± 0.06 and 0.05% ± 0.09), MDA
(−0.11% ± 0.03 and −0.17% ± 0.03), 8-OHdG (43.25% ± 3.01 and 42.70% ± 3.27) in
the CON and PRO groups, respectively.We concluded that the cognitive and biochemical
indications in the patients with severe AD are insensitive to the probiotic supplementation.
Therefore, in addition to formulation and dosage of probiotic bacteria, severity of disease
and time of administration deeply affects results of treatment.
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INTRODUCTION
Alzheimer’s disease (AD) is a common neurodegenerative
disease accounting for 60–80% of all dementia (1). It is
characterized by progressive declines in cognitive and functional
abilities, neuropsychiatric symptoms, caregiver burden and
premature death (2). Particularly, it is accompanied with
early impairment of episodic memory (3, 4) followed by
progressive deficits in short term memory leading to a final
procedural memory deficit (5). AD is etiologically resulted of
the extracellular accumulation of amyloid-β plaques, formation
of neurofibrillary tangles, neuroinflammation, neuronal injury,
and synapse loss (6). In recent studies, neuroinflammation and
oxidative stress are particularly considered for their important
role in the pathogenesis of AD (7, 8). Especially, growing
evidences indicate that both oxidative stress and inflammation
are involved in the mechanisms associated with Aβ-induced
neurotoxicity (9).
Cholinesterase inhibitors such as donepezil, rivastigmin, and
galantamin are approved for treatment of mild to moderate
degree of AD. Also the partial NMDA receptor antagonist
memantin is prescribed in the moderate to severe of AD
(10). However, in spite of fanciful advances in therapeutic
aims, AD still lack effective medications. Therefore, novel and
effective treatments research have focused on other resources
of treatment (11). The microbiota, the ecological community of
commensal, symbiotic, and pathogenic microorganisms literally
sharing our body space, includes more than 10 times the
number of host cells to human cells (12). Emerging studies
indicate that the microbiota may contribute to the regulation of
multiple neurochemical and neurometabolic pathways through
a complex series of highly interactive and symbiotic host-
microbiome signaling systems (13–15). This interconnection of
the gastrointestinal tract and the central nervous system (CNS)
is known as microbiota-gut-brain axis (16) that regulates brain
function and behavior. Emerging data demonstrates that certain
pathologies, related to an altered microbiome, are linked to
mood, stress, behavior, and cognition (17). Some complications
such as cognitive disorders, oxidative stress, neuroinflammation,
which are also observable in AD, are identified to be influenced
by the gut flora as well as probiotics. Probiotics are defined as
the living microorganisms with the beneficial effects for humans
and animals when administered in a sufficient number. The most
commonly used probiotics are the strains of lactic acid bacteria
such as Lactobacillus and Bifidobacterium. Preclinical research
shows that probiotics may improve cognitive performances in the
animal models with impaired cognition (18). It is reported that
probiotics inhibit oxidative stress via reducing inflammation and
increasing antioxidant enzymes such as superoxide dismutase
and glutathione peroxidase (19).
Test Your Memory (TYM), introduced by Brown et al. (20),
is a brief test designed to detect AD. It includes a series of 10
cognitive tasks consists of orientation, ability to copy a sentence,
semantic knowledge, calculation, verbal fluency, similarities,
naming, visuospatial abilities, ability to do the test and recall of a
copied sentence giving a possible total of 50 scores. Importantly,
the developers of the test believe that education and social class
have only mild effects on the TYM score (20).
In our previous work we reported for the first time the
effect of a probiotic supplementation on the cognitive as well
as metabolic status of the patients with AD (21). In the present
work using a different formulation of probiotic combination we
applied the TYM test as a cognitive tool to assess the cognitive
status of the people suffering from AD treated by a mixture of
probiotic bacteria. Further, because of deep changes in balance
of the oxidant/antioxidant and inflammatory/anti-inflammatory
biomarkers in the AD, in the present work we also considered
how the serum concentration of the inflammatory and oxidative
biomarkers responds to the oral bacteriotherapy.
MATERIALS AND METHODS
Participants
This clinical study was performed as a randomized, double-
blind, and placebo-controlled clinical trial. Participants included
in this study were people with AD (65–90 years old) residing
at Emam Ali (Tehran, Iran), Golabchi (Kashan, Iran), Miad
(Kashan, Ravand, Iran), and Barekat (Aran and Bidgol, Iran)
Welfare Organizations between June 2017 and August 2017. AD
patients were diagnosed based on the NINDS-ADRDA criteria
(22) and revised criteria from the National Institute on Aging-
Alzheimer’s Association (23). For further proof the AD patients
were compared with the cognitively intact people based on the
TYM cognitive test. Accordingly, the participants gaining TYM
scores in level of AD (<45 out of 50 scores) were entered the
study (see section “Results” for details). Patients with metabolic
disorders, chronic infections and/or other clinically relevant
disorders were excluded from the study. Standard formula for
clinical trials was used to calculate sample size for the study.
Based on a previous study (24), considering type one error (α) of
0.05 and type two error (β) of 0.20 (power= 80%) we used 1.3 as
SD and 1.1 as the difference in mean (d) of TYM as key variable.
Accordingly, we needed 25 persons in each group. Assuming 5
dropouts in each group, the final sample size was determined
to be 30 persons per group. Figure 1 explains flow of subject
selection assigned as CON and PRO groups enrolled in the study.
Ethical Approves
This clinical trial was done in accordance with the Helsinki
Declaration of 1975. Also, performing the study was approved by
the ethics committee of Kashan University of Medical Sciences
(KUMS) and registered in the Iranian Website for Registration
of Clinical Trials IRCT (IRCT number: 2017061534549N1).
Written Informed consent was received from all patients.
Study Design
At the onset of the study, all subjects were matched for disease
severity based on gender, BMI, and age. Participants were then
randomly divided into two groups: the control (CON) group
(n = 23 including 13 females and 10 males) receiving placebo
capsules containing 500mg maltodextrine and, the probiotic
(PRO) group (n = 25: 18 females and 7 males) receiving
capsules containing a mixture of probiotic bacteria (see below for
details). The treatment was lasted for 12 weeks. Participants were
requested to have no change in their regular physical activity and
consume no nutritional supplements during the clinical trial.
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Intervention
It would be more appropriate to use strains of probiotics for
human consumption derived from the human intestinal tract,
well characterized, able to outlive the rigors of the digestive tract
and possibly colonize, biologically active against the target as
well as to be stable and amenable to commercial production
and distribution (25). Very rare reports are evident about
effectiveness of probiotic bacteria on cognitive phenomena
(26–29). In our previous works we tested mixtures of probiotics
containing both Lactobacillus and Bifidobacterium genera
(Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus
fermentum, and Bifidobacterium bifidum). In the present
study we tested the effect of other multispecies probiotics
containing different stains and species of the genera Lactobacillus
and Bifidobacterium. We prepared two types of capsules
each containing 3 bacteria (with a total dosage of 3 × 109
CFU) including either Lactobacillus fermentum, Lactobacillus
plantarum, and Bifidobacterium lactis (provided by Zist
Takhmir Company, Tehran, Iran) or Lactobacillus acidophilus,
Bifidobacterium bifidum, and Bifidobacterium longum (provided
by Milad Farmed Company, Tehran, Iran). The probiotic group
received one of each capsule every other day.
Anthropometric Considerations
Weight and height of the participants were determined in an
overnight fasting status using a standard scale (Seca, Hamburg,
Germany) before and 12 weeks after the treatment. BMI was
calculated as: weight (Kg)/height (m2).
Outcome Evaluation
The TYM test was used to evaluate the level of cognition in the
patients and the TYM results were considered as the primary
outcomes. However, the two questions in the semantic knowledge
section of the TYM were substituted by questions familiar to
Iranian people. In the first question the subjects were asked to
name the Iranian president rather than the UK prime minister.
Also the second question of semantic knowledge “In what year
did the 1stWorldWar start?” uncommon knowledge in Iran, was
changed to “In what year did the war between Iran and Iraq?”
As a secondary outcome the findings of the oxidative stress and
inflammatory biomarkers were assessed.
Assessment of Biochemical Parameters
Twelve-hour fasting blood samples were collected by
venipuncture before and after the intervention. The blood
samples were taken according to a standard protocol and
centrifuged (Hettich D-78532, Tuttlingen, Germany). Then,
the samples were stored at −80◦C until analysis. Serum total
antioxidant capacity (TAC) was quantified using the method
of ferric reducing antioxidant power method developed by
Benzie and Strain (30). The method of Beutler et al. was used for
measuring total glutathione (GSH) (31). Plasma concentration
of malondialdehyde (MDA) was measured by the thiobarbituric
acid reactive substance method (32).
The serum high sensitivity concentrations of IL-6, IL-
10, and TNF-α were measured using commercial ELISA kit
(Diaclone, French). Serum high sensitivity 8-hydroxy-2′ -
deoxyguanosine (8-OHdG) concentration was also quantified by
use of commercial ELISA kit (Zelbio, Germany). Plasma nitric
oxide (NO) was quantified by the Griess method (33).
Statistical Methods
Kolmogrov-Smirnov test was applied to the data to determine
normal distribution of the variables. Possible differences in
anthropometric measures were detected using unpaired student
t-test. The effect of probiotic supplementation on the TYM
cognitive test, oxidative stress biomarkers, and inflammatory
factors, determined by one-way analysis of variance (ANOVA)
followed by Tukey’s post test. The change before and after the
intervention was calculated as: % (post-treatment value–pre-
treatment value)/ pre-treatment value. The differences between
the healthy and AD participants, between the participants with
moderate and severe AD, and between the changes in the CON
and PRO groups were determined by unpaired student t-test.
The data are reported as mean ± SEM. The differences were
significant if P value was <0.05. All statistical analyses were
performed using SPSS—version 18.
RESULTS
Anthropometric Characteristics of the
Patients
The patients assigned to the CON and PRO groups weighed
80.57 ± 1.79 and 79.70 ± 1.72 kg, respectively at the onset of the
study. BMI index of the subjects enrolled in the study showed
no difference over 12 weeks. The change percent of BMI was
0.11 ± 0.29 and 0.74 ± 0.34 in the CON and PRO groups (P >
0.05), respectively (Table 1).
Confirmation of Alzheimer’s Disease in the
Patients Based on the TYM Cognitive Test
The TYM test was used to further confirm the healthy and
Alzheimer’s subjects. TYM is a cognitive tool designed for
detection of AD that includes 10 cognitive tasks with a total
of 50 scores. Therefore, the participants were firstly introduced
to the TYM cognitive test. The subjects assigned as cognitively
intact people gained an average of 44.55 ± 0.37 scores. This
value is near to the criterion in the TYM test (34) to confirm
lack of any dementia. On the other hand, the people assigned
as AD patients committed an average of 14.51 ± 1.40 scores.
TABLE 1 | Anthropometric characteristics of the patients.
CON group
(n = 23)
PRO group
(n = 25)
P value
Gender Male 10 7 0.42
Female 13 18 0.25
Age (year) 80.57 ± 1.79 79.70 ± 1.72 0.36
Weight (kg) Before treatment 60.63 ± 1.26 60.12 ± 1.12 0.42
After treatment 60.58 ± 2.36 60.32 ± 1.42 0.48
Height (cm) 156.43 ± 1.86 156.77 ± 1.23 0.38
BMI (kg/m2) Before treatment 24.44 ± 1.33 24.05 ± 1.07 0.47
After treatment 24.56 ± 1.34 24.21 ± 1.06 0.45
CON, control; PRO, Probiotic.
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FIGURE 1 | Summary of patient flow.
Such a score in the TYM test fall in range of severe AD
(scores <25). Unpaired student t-test indicated a considerable
significant (P < 0.0001) between the cognitively intact people
and those with AD (Figure 2). Then, the AD patients were
divided in to two CON and PRO group treated by placebo
(maltodextrine) and probiotic bacteria, respectively. Of them,
a majority of 83.5% showed a severe AD and the rest (16.5%)
had a moderate disease. The people with severe AD gained
10.63 ± 1.35 score and those with moderate AD gained
28.7 ± 4.47 score. The scores achieved by the moderate and
severe AD patients entered the study are illustrated in the
Figure 3. In the CON patients 17.86% were fallen in a range of
moderate AD committing a mean score of 30 ± 4.62. The rest
(82.14%) of the patients fell in a range of severe AD, gaining a
score of 9.57± 1.37. In the PRO group, 16.13% of patients gained
27.14± 4.32 scores showing a moderate AD. The rest of patients
(n = 26, 83.87%) gained 11.69 ± 1.33 scores confirming a severe
disease. Consequently, the percentage of patients with mild and
severe disease was almost the same in both CON and PRO
groups.
The Effect of Probiotic Supplementation on
TYM Test
The TYM cognitive test was taken from the CON and PRO group
before and 12 weeks after the intervention. The pre- and post-
treatment TYM scores in the PRO group were 14.64 ± 1.71
and 17.42 ± 2.42, respectively; the values in the CON patients
were 14.35 ± 2.27 and 17.47 ± 2.89, respectively (Table 2).
Analysis of variance indicated no difference between the two
groups [F(3, 114) = 0.29, P < 0.82]. The change percent between
the scores achieved at the onset and offset of the trials was
12.86% ± 8.33 in the CON group and −9.35% ± 16.83
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FIGURE 2 | The scores of the TYM test achieved by the cognitively intact people and those with Alzheimer’s disease (AD). The scores gained by the cognitively intact
and AD participants were 44.55 ± 0.37 against 14.51 ± 1.40, respectively. Unpaired student t-test indicated a significant difference between the two groups
(***P < 0.0001).
FIGURE 3 | The TYM scores achieved by the patients with moderate and severe Alzheimer’s disease (AD); the former group gained 28.7 ± 4.47 score and the latter
10.63 ± 1.35 score. Unpaired student t-test showed a significant difference between the two AD groups (***P < 0.0001).
in the PRO group, however, the unpaired student t-test
indicates no statistical difference between the two groups
(Table 3).
Inflammatory/Anti-Inflammatory Factors
Analysis of variance applied on the data taken from the CON
and PRO groups showed that treatment of the AD patients with
the probiotic supplementation not significantly affected TNF-
α [F(3, 63) = 0.64; P > 0.05], IL-6 [F(3, 71) = 0.27; P > 0.05],
and IL-10 [F(3, 63) = 0.64; P > 0.05]. The change percent in the
serum level of TNF-α, IL-6, and IL-10 in the CON group was
0.35% ± 0.17, −1.67% ± 1.33, and 0.05% ± 0.10, respectively.
The values in the PRO group were−0.15%± 0.27, 2.18%± 0.15,
and −0.70% ± 0.73, respectively. The pre- and post-treatment
values are shown in the Table 2 and the change percent are given
in the Table 3.
Oxidants/Antioxidants Factors
A general statistical difference was observed concerning TAC
between the two group [F(3, 81) = 4.42, P < 0.01]. However,
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TABLE 2 | Pre- and post-treatment cognitive scores and biochemical values in the CON and PRO groups.
CON group PRO group Difference between the
two groups
Pre-treatment Post-treatment Pre-treatment Post-treatment P value
TYM (score out of 50) 14.35 ± 2.27 17.47 ± 2.89 14.64 ± 1.71 17.42 ± 2.42 0.82
TAC (µmol/L) 868.75 ± 42.45 885.72 ± 29.05 1029.97 ± 23.41 937.07 ± 16.06 <0.01
GSH (µmol/L) 640.78 ± 19.77 731.55 ± 37.33 727.82 ± 22.01 759.01 ± 28.29 >0.05
MDA (µmol/L) 3.07 ± 0.07 2.98 ± 0.07 3.20 ± 0.07 2.87 ± 0.06 <0.05
NO (µmol/L) 39.12 ± 1.81 47.75 ± 3.45 35.94 ± 2.43 38.06 ± 0.75 <0.01
TNF-α(pg/ml) 0.63 ± 0.03 2.13 ± 1.07 1.89 ± 0.72 1.56 ± 0.44 >0.05
IL-10(pg/ml) 0.59 ± 0.01 0.76 ± 0.17 0.73 ± 0.12 0.59 ± 0.01 >0.05
IL-6(pg/ml) 3.58 ± 1.04 3.37 ± 1.41 3.42 ± 0.61 4.51 ± 1.29 >0.05
8-OHdG(ng/ml) 43.72 ± 6.31 41.80 ± 6.19 43.25 ± 3.01 42.70 ± 3.27 >0.05
The values in the two groups are compared by one-way ANOVA followed by Tukey’s post-test.
CON, control; PRO, Probiotic.
TABLE 3 | Comparison of the change percent of the biochemical factors between
the control and probiotic groups.
CON Group
(Change%)
PRO group
(Change%)
P value
TYM (score out of 50) 0.12 ± 0.08 −9.35 ± 16.83 >0.05
TAC (µmol/L) 0.07 ± 0.07 −0.06 ± 0.03 0.058
GSH (µmol/L) 0.08 ± 0.05 0.04 ± 0.03 0.26
MDA (µmol/L) −0.11 ± 0.03 −0.17 ± 0.03 0.11
NO (µmol/L) 0.11 ± 0.06 0.05 ± 0.09 0.30
TNF-α (pg/ml) 0.35 ± 0.17 −0.15 ± 0.27 >0.05
IL-10 (pg/ml) 0.05 ± 0.10 −0.70 ± 0.73 >0.05
IL-6 (pg/ml) −1.67 ± 1.33 2.18 ± 0.15 <0.001
8-OHdG (ng/ml) −0.33 ± 0.37 −0.02 ± 0.12 0.21
The values between the two groups were compared by unpaired student t-test.
CON, control; PRO, Probiotic.
within group analysis indicated no considerable difference
between the pre- and post-treatment values in the two groups.
The change percent in the CON and PRO groups were
0.07%± 0.07 and−0.06%± 0.03, respectively.
We observed no variation in the serum level of GSH in the two
testing groups [F(3, 82) = 4.25, P > 0.05]. The change percent in
the CON and PRO groups were 0.08% ± 0.05 and 0.04% ± 0.03,
respectively.
Although ANOVA showed a significant difference in serum
level of NO between the CON and PRO patients [F(3, 81) = 4.42,
P < 0.01, Table 2], however, the post-hoc test indicates that
the change percent in the CON (0.11% ± 0.06) and PRO
(0.05% ± 0.09) groups was ignorable (Table 3). Despite ANOVA
confirms a general variation in the MDA concentration of serum
in the CON and PRO groups [F(3, 82) = 3.50, P < 0.05, Table 2]
the post-test indicates a negligible change percent of MDA in
the CON (−0.11% ± 0.03) and PRO (−0.17% ± 0.03) patents
(Table 3). The pre- and post-treatment change in the serum level
of the DNA degrading factor 8-OHdG showed not statistically to
be considerable [F(3, 71) = 0.02, P > 0.05]. The change percent
values are −0.33 ± 0.37 and −0.02 ± 0.12, respectively. The
Table 2 explains analysis of pre- and post-treatment values in
the CON and PRO AD patients based on ANOVA. The change
percent in the CON and PRO groups analyzed based on unpaired
student t-test are shown in Table 3.
DISCUSSION
The pathologic features of AD are multifaceted, including
precipitation of extracellular amyloid-β plaques, formation of
intracellular neurofibrillary tangles and damage to neuronal
synapses (28). However, these aspects of AD are easily
researchable in experimental studies on animal models.
Therefore, in level of investigation, histological changes in the
AD patients were not under focus of this study. Despite, some
other indications which are also observable in AD patients are
measurable in clinical researches. Hence, this study was devoted
to evaluation of alterations in the oxidants/antioxidant and
inflammatory/anti-inflammatory factors as well as cognitive
status in the AD patients.
We asked if reinforcement of the gut microbiota by probiotic
bacteria influences the cognitive as well as biochemical disorders
in the AD patients. Using the TYM test, cognitive status of the
ADpatients was analyzed. As illustrated in the Figure 2 the scores
achieved by the AD patients are less than one third compared to
the cognitively intact people, confirming a real dementia in the
group assigned as AD. The AD patients were given a formula
of probiotic supplementation consisting both Lactobacilli and
Bifidobacteria. The cognitive TYM assessment indicated no
difference between the CON and PRO groups. Our results
showed that the intervention not pronouncedly influenced either
inflammatory (TNF-α and IL-6) or anti-inflammatory (IL-10)
factors. Also, our findings indicated that the oral bacteriotherapy
had no considerable effect on the oxidants (MDA and 8-OHdG)
or antioxidant (TAC, GSH) factors.
In healthy humans, there is a close mutualistic and symbiotic
relationship between gut microbiota and the body. This normal
state of the human intestinal microbiota is called eubiosis.
Any distortion from eubiosis, linked with whether a decrease
of intestinal biodiversity or increase of pathogenic bacteria,
is called dysbiosis. The dysbiosis results in alteration of the
immune system of the gut mucosa and the rise of inflammatory,
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immune, metabolic or degenerative diseases (35). Emerging
evidence indicates that change in gut microbiota composition
may contribute in some neurological disorders. Therefore,
intervenes like antibiotics, probiotics, pathogens, and nutrition
are expected to affect the composition of gut microbiota and
physiological function of gut and, thus, influence the host
cognitive behavior and change the risk of AD (36). Particularly,
nutritional interventions are now promising as strategies to treat
or at least delay AD progression.
Very rare preclinical findings are evident on the effect
of probiotic supplements on AD. Recently, Bonfili et al.
reported that treating an animal model of AD (mice 3xTg-
AD) with a probiotic formulation (SLAB51) positively interfere
with inflammatory cytokines and concentration of some gut
hormones, reduce amyloid-β plaques and improve cognitive
function (26). In another study Nimgampalle and Kuna revealed
that Lactobacillus plantarum MTCC1325 might have anti-
Alzheimer properties against D-Galactose induced AD (27).
Further support was provided by Peng et al. where they reported
that the probiotic bacteria Lactobacillus plantarum NDC75017
improves the learning and memory ability in aging rats (37).
Also Distrutti et al. demonstrated that a formulation of probiotic
(VSL#3) positively affected inflammatory and neuronal processes
and restored impaired synaptic plasticity (38). In a research
on healthy humans Chung et al. reported that fermented
milk containing Lactobacillus helveticus IDCC3801 improves
cognitive function in healthy older adults (29).
We were the first to present a clinical work demonstrating
a favorable effect of probiotic bacteria on the patients with
AD. Three months treating the AD patients with a probiotic
formulation containing four bacteria (Lactobacillus acidophilus,
Lactobacillus casei, Lactobacillus fermentum, and Bifidobacterium
bifidum) slightly improved cognitive indices, increased some
antioxidant factors and normalized some lipid profiles (21).
However, compared to the previous work, more ADpatients were
fallen in severe stage in the present study (83.5 vs. 67%) and
less in moderate stage (16.5 vs. 33%). In another clinical trial
we also found positive effect of a probiotic supplementation on
motor behavior, and plasma level and gene expression of some
biochemical indices in the people with multiple sclerosis (39, 40).
Lack of inflammatory biomarkers measurement in the AD
patients was considered as a limitation in our previous work.
Hence, in the present study the inflammatory cytokines TNF-α,
IL-6, and IL-10 were evaluated. Increased TNF-α is known as a
key element in inflammatory cascade that in turn increases the
amyloid-β and tau pathology in AD (41). Evidence indicates an
enhanced expression of IL-6 in both the periphery (42) and the
CNS (43) in AD patients. Concerning IL-10, both positive (44)
and negative (45) effects of this cytokine on cognition of AD
animal models are reported. However, the probiotic supplement
used in this study had no effect on either inflammatory or
anti-inflammatory parameters in the AD patients. Some other
inflammatory biomarkers related to the cognitive disorders must
also be considered. Two of them are S100A12 and neopterin,
known as intestinal and systemic inflammatory biomarkers,
respectively. In a recent work Leblhuber et al. found a close
correlation between fecal S100A12 and serum neopterin in
cognitive disorders like AD; signifying a role of gut inflammation
as a possible pathogenic cofactor in cognitive deterioration and
dementia (34).
A key mechanism associated with AD is oxidative stress
(46) that might be modified through nutritional or antioxidant
supplements (47). Our findings indicated no effect of the
probiotic supplementation on either oxidant or antioxidant
biomarkers. In a clinical trial Tramutola et al. reported that AD
patients were irresponsible to the administered antioxidants (48).
They concluded that clinical trials of drugs with only a single
mechanism against AD at the dementia stage might be expected.
Findings of this clinical trial indicated that treatment
of the AD patients with a formulation of the probiotic
bacteria effectively influenced neither the cognitive function nor
biochemical factors. In our previous work on the AD patients we
found a favorable effect of a different probiotic supplementation
on both the cognition and some of biochemical statuses. We
think that the difference between results of the two studies could
be attributed to the different probiotic formulation and severity
of the disease. However, some other reasons might explain why
application of supplements on aged patients such as people with
AD no sufficiently affects the cognitive and biochemical factors.
A reason could be the protocol including the duration of the
supplement administration. In a recent clinical trial conducted
on more than 7,000 men with AD Kryscio, et al found that
supplements containing vitamin E, selenium, or vitamin E +
selenium had no effect on dementia (49). Also, wrong timing of
administration may be responsible for the failure of supplements
to influence the age associated disorders where, in sever stage
of AD, the loss of synapses and development of neurofibrillary
tangles are irreversible pathological changes (50). Concomitantly,
the use of probiotic at this stagemay not be successful in reversing
the disease process. Eventually, it is worthwhile to imply that
inflammatory/oxidative stress pathways are not specific to AD
and are sensitive pathways involved in many diseases. Thus, we
have tested the effect of probiotic supplementation on cytokines
and oxidative stress pathways that might be only a part of the
pathophysiology of the AD.
Conclusively, inconsistent effects of supplements on
neurological disorders in aged people must not be interpreted as
paradoxical results. Other intervenes including age and severity
of disease must be considered in future studies.
There were some limitations that influenced our study;
importantly inclusion of people mostly in severe stage of
AD, small number of subjects included in the study, the
dosage and formulation of probiotic bacteria, and a sort
supplement exposure time. Additionally, assessment of the
impaired cognitive related inflammatory biomarkers, S100A12,
and neopterin, are suggested in future investigations on AD
patients.
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